British researchers plan to begin testing a potential diabetes vaccine on human patients next summer. The vaccine contains a molecule identical to part of the insulin-producing islet cells and when added to human blood can form protective cells to block white blood cells that attack the islets. The vaccine was developed by Clinalfa, a Merck subsidiary.

Related Summaries